Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
PHASE3CompletedINTERVENTIONAL
Enrollment
252
Participants
Timeline
Start Date
August 12, 2014
Primary Completion Date
November 3, 2017
Study Completion Date
November 3, 2017
Conditions
Crohn's Disease
Interventions
DRUG
Adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection